Opinion|Videos|September 19, 2024

Highlights from WCLC 2024: CheckMate -77T vs. CheckMate -816

Panelists discuss how the latest outcomes from CheckMate-77T demonstrate improved efficacy of neoadjuvant immunotherapy in early-stage non–small cell lung cancer compared with CheckMate-816, potentially revolutionizing treatment strategies and enhancing long-term survival rates for patients with lung cancer.


Latest CME